About CLINUVEL

NICE MAINTAINS ITS POSITION NOT TO RECOMMEND SCENESSE® FOR REIMBURSEMENT

NICE MAINTAINS ITS POSITION NOT TO RECOMMEND SCENESSE® FOR REIMBURSEMENT
CLINUVEL TO APPEAL NICE DECISION IN ENGLAND

Melbourne, Australia, and Leatherhead, UK, 23 May 2018

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY) today announced that the English National Institute of Health and Care Excellence (NICE) maintained its position not to recommend CLINUVEL’s drug SCENESSE® (afamelanotide 16mg) for reimbursement in England (see ASX announcement 21 December 2017). In its evaluation of novel medicinal therapies NICE advises the English National Health Service (NHS) whether a proposed therapy meets its economic criteria for reimbursement or not. CLINUVEL will now proceed to appeal the decision taken by NICE.
NICE published its draft Final Evaluation Document (FED) overnight, Australian time, and the Highly Specialised Technologies (HST) Committee of NICE maintained that SCENESSE® did not meet its health-economic criteria for reimbursement under the English NHS for the treatment of adult patients diagnosed with the ultra-rare genetic disorder erythropoietic protoporphyria (EPP).1 In December 2017 CLINUVEL announced that the HST Committee, in its preliminary assessment, did not recommend SCENESSE®. Pharmaceutical therapies recommended by NICE must be made available to patients under the NHS.

NICE EVALUATION PROCESS
As part of the evaluation process, CLINUVEL first engaged with NICE’s affiliated organisations from 2012 onwards and was invited to participate in a workshop on EPP in March 2016. The Company was required to make a formal submission to NICE in 2017 and has attended two public meetings of the HST Committee.
During the second public HST Committee meeting on 20 February, representatives of NICE, CLINUVEL and the HST Committee discussed the alternative of a managed access agreement (MAA), whereby patients are given access to the product via a commercial agreement between CLINUVEL and the NHS. Discussions between CLINUVEL and NICE are ongoing.

APPEAL TO EXTEND NICE REVIEW INTO THIRD YEAR
CLINUVEL will appeal the decision taken by NICE. The duration and extent of the appeal process is currently unknown.

COMMENTARY
“It is most disappointing that English EPP patients will not have access to the only approved medication for a debilitating condition, one not well understood by authorities,” CLINUVEL’s European General Manager, Mr Lachlan Hay said. “The length of time of the review by NICE is unacceptable, particularly in the context of this unique and rare disorder, and it appears that EPP patients in England must endure at least one more year of isolation and anxiety while an increasing number in Europe are granted reimbursement for this medication.
“I am hopeful that we will succeed in overcoming the English decision. Pragmatic solutions have been found elsewhere thus far, owing to CLINUVEL’s open and sincere approach to authorities, and several procedural options remain available to secure treatment for English patients. Through its ongoing controlled distribution of SCENESSE® in Europe, CLINUVEL is able to demonstrate to third parties responsible for making health-economic decisions on behalf of national governments, how it is able to minimise or remove risks and uncertainties of the treatment provided,” Mr Hay said.

- End -

¹ SCENESSE® (afamelanotide 16mg) is approved in Europe as an orphan medicinal product for the prevention of phototoxicity in adult patients with EPP. Information on the product can be found on CLINUVEL’s website at www.clinuvel.com.

About CLINUVEL PHARMACEUTICALS LIMITED
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead product, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care
Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore.
For more information go to http://www.clinuvel.com.

SCENESSE® is a registered trademark of CLINUVEL PHARMACEUTICALS LTD.

Media enquiries
Lachlan Hay, CLINUVEL (UK) LTD,     +44 1372 860 765     This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor enquiries
This email address is being protected from spambots. You need JavaScript enabled to view it.

Forward-Looking Statements
This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. Statements may involve a number of known and unknown risks that could cause our future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg); our ability to achieve expected safety and efficacy results through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; any failure to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2017 Annual Report. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on the forecasts


Level 6, 15 Queen Street       T +61 3 9660 4900      www.clinuvel.com
Melbourne, Victoria 3000       F +61 3 9660 4999
Australia
EUROPEAN POST-AUTHORISATION PROGRAM
CLINUVEL’s first-line therapeutic SCENESSE® (afamelanotide 16mg) was approved by the European Medicines
Agency (EMA) in 2014 for adults with EPP.1 The Company has committed to long-term pharmacovigilance and risk
minimisation measures – following up patients longer term – and a controlled product distribution program in
Europe.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a favourable opinion on the benefitrisk
profile of the product following its review of CLINUVEL’s third post-authorisation Annual Report (AR) on
SCENESSE®. The CHMP review assessed the first extensive safety and effectiveness data from patients registered in
the European EPP Disease Registry (EEDR) who had received up to six SCENESSE® implants. Over 85% of European
EPP patients treated to date have agreed to have their pseudonymised data included in the EEDR for analysis.
Since marketing authorisation CLINUVEL has submitted six-monthly periodic safety update reports (PSURs) to the
CHMP to provide an overview of the ongoing safety profile of the product and implementation of risk minimisation
measures (RMMs). The sixth PSUR – covering the second half of 2017 – provided a comprehensive overview of the
safety profile from the use of SCENESSE®, with no new safety concerns identified and excellent ongoing compliance
with RMMs across Europe. Of significance, the most recent PSUR confirmed that no off-label use of SCENESSE® had
occurred for the period, an indication of the success of the control of the distribution program.
To date more than 5,100 SCENESSE® implants have been administered worldwide, with more than 4,000
administered to EPP patients across clinical trials, compassionate use and special access programs, and postauthorisation
use in Europe. A cohort of patients in Switzerland have received ongoing treatment for more than 12
consecutive years, with some receiving more than 50 SCENESSE® implants over this period.
US NEW DRUG APPLICATION (NDA) FILING
CLINUVEL has now incorporated these analyses into its New Drug Application (NDA) for the US Food and Drug
Administration (FDA), following their acceptance by the EMA. An approved NDA will allow CLINUVEL to make
SCENESSE® available for adult EPP patients in the US. The final submission of the NDA dossier is expected before 1
July 2018.
2
NEW PRODUCT DEVELOPMENT
The EMA’s positive assessment of the AR and PSUR have an impact on CLINUVEL’s ongoing scientific research, with
several therapeutic products under development by the Group’s Singaporean operations, VALLAURIX. The scientific
focus is currently on the development of complementary non-prescriptive products as well as follow-on products to
address unmet medical need in severe and genetic disorders. The first product line is expected to be announced in
July 2018 following the completion of the NDA submission.
In addition to developing non-prescription products, the VALLAURIX team is working to establish an appropriate
formulation of afamelanotide for paediatric use – SCENESSE® ENFANCE – as well as progressing the scientific work
towards the novel molecules CUV9900 and VLRX001.
COMMENTARY
“We are delighted that the largest ever number of EPP patients are currently receiving treatment, and thank the
European physicians, hospital staff, and patients for their ongoing support,” CLINUVEL’s Director of Clinical Affairs,
Dr Emilie Rodenburger said. “It gives our team great satisfaction that we are able to expand access for patients who
have no therapeutic alternatives.
“The exemplary treatment compliance rate reported – with more than ninety-nine percent of patients remaining on
treatment – continues to be seen in Europe. Most importantly for the future of our pipeline, SCENESSE® continues
to maintain a positive safety profile under conditions of use in the clinic,” Dr Rodenburger said.
“Feedback from the European EPP program has been invaluable to strengthening the NDA dossier as well as
progressing our innovative R&D in Singapore,” CLINUVEL’s Acting Chief Scientific Officer, Dr Dennis Wright said.
“The team’s focus on compliance with strict measures has positioned us to harmonise our European program with
one to be conducted in the US, ensuring appropriate use of SCENESSE®.”
– End –

Additional Info

  • customtext: CLINUVEL PHARMACEUTICALS LTD today announced that the English National Institute of Health and Care Excellence (NICE) maintained its position not to recommend CLINUVEL’s drug SCENESSE® (afamelanotide 16mg) for reimbursement in England.